FDA approves first self-balancing exoskeleton for spinal cord patients

Summary

The FDA has approved the commercial sale of the Wandercraft Eve exoskeleton, designed for spinal cord injury patients to maintain their own balance. This approval makes Eve the first personal exoskeleton of its kind on the US market.

Why it matters

For individuals living with tetraplegia or paraplegia, standing independently, cooking, or brushing their teeth represents a profound improvement in quality of life that wheelchairs cannot provide. However, the device is designed exclusively for indoor use on flat surfaces. It has a speed limit of 0.25 m/s and requires a caregiver to be present at all times. Consequently, the device focuses on a narrow slice of daily life rather than restoring true mobility.

Highlights

• 12 hip/knee/ankle motors and built-in sensors enable self-balancing without the need for canes or walkers
• 16-patient study: 87.5% completed the full six-day task; 17 safety events were recorded, mostly skin irritation and one fall without injury
• Strict limitations: indoor flat surfaces only, max 100 kg / 1.94 m, caregiver must always be present, 4-hour battery life

Critical take

The headline “World’s first self-balancing exoskeleton” exaggerates a device that cannot be used on stairs, curbs, wet floors, or public roads and requires a trained caregiver at all times. With only a 16-patient study and undisclosed pricing, the evidence base and accessibility story for this product, marketed as a mainstream medical device, remain weak.